Ascendis Pharma A/S- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Ascendis Pharma A/S 公司

Ascendis Pharma A/S 是一家總部位於丹麥的製藥產品生產公司。該公司生產的產品用於治療生長激素缺乏症、內分泌學、中樞神經系統疾病、傳染病和糖尿病。該公司通過其子公司在全球開展業務：Ascendis Pharma GmbH（德國）、Ascendis Pharma, Inc.（美國特拉華州）、Ascendis Pharma Endocrinology, Inc.（美國特拉華州）、Ascendis Pharma, Ophthalmology Division A/S（丹麥）、Ascendis Pharma, Endocrinology Division A/S（丹麥）、Ascendis Pharma Bone Diseases A/S（丹麥）、Ascendis Pharma Growth Disorders A/S（丹麥）和 Ascendis Pharma Oncology Division A/S（丹麥）。

公司簡介

公司代碼ASND

公司名稱Ascendis Pharma A/S

上市日期Jan 28, 2015

CEOMr. Jan Moller Mikkelsen

員工數量- -

證券類型Depository Receipt

年結日Jan 28

公司地址Tuborg Boulevard 12

城市HELLERUP

上市交易所NASDAQ Global Select Consolidated

國家Denmark

郵編2900

電話4570222244

網址https://ascendispharma.dk/

公司代碼ASND

上市日期Jan 28, 2015

CEOMr. Jan Moller Mikkelsen

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Michael Wolff Jensen

Executive Vice President, Chief Legal Officer, Member of the Executive Board

5.76K

+198.45%

Mr. Flemming Steen Jensen

Executive Vice President, Product Supply and Quality

1.86K

+100.43%

Mr. Lars Holtug, CPA

Independent Director

1.59K

+78.59%

Ms. Lisa Bright

Independent Director

1.09K

+178.01%

Dr. Albert Cha, M.D., Ph.D.

Independent Chairman of the Board

1.09K

+178.01%

Ms. Siham Imani

Independent Director

364.00

--

Mr. Mads Bodenhoff

Senior Vice President, Head of Finance and Principal Accounting Officer

193.00

--

Mr. Donovan (Jay) Wu

Executive Vice President, U.S. President

--

Dr. Aimee Shu,, M.D.

Executive Vice President, Chief Medical Officer

--

Mr. William Carl (Bill) Fairey, Jr.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Michael Wolff Jensen

Executive Vice President, Chief Legal Officer, Member of the Executive Board

5.76K

+198.45%

Mr. Flemming Steen Jensen

Executive Vice President, Product Supply and Quality

1.86K

+100.43%

Mr. Lars Holtug, CPA

Independent Director

1.59K

+78.59%

Ms. Lisa Bright

Independent Director

1.09K

+178.01%

Dr. Albert Cha, M.D., Ph.D.

Independent Chairman of the Board

1.09K

+178.01%

Ms. Siham Imani

Independent Director

364.00

--

收入明細

單位: EUR更新時間: 7月6日週日

FY2025Q1

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務EUR

名稱

營收

佔比

Commercial sale of products

96.03M

95.12%

Rendering of services

3.52M

3.49%

License

1.40M

1.39%

地區EUR

名稱

營收

佔比

North America

73.69M

72.99%

Europe

21.33M

21.13%

Rest of world

5.94M

5.88%

業務

地區

業務EUR

名稱

營收

佔比

Commercial sale of products

96.03M

95.12%

Rendering of services

3.52M

3.49%

License

1.40M

1.39%

股東統計

更新時間: 9月5日週五

持股股東

股東類型

持股股東

佔比

RA Capital Management, LP

17.03%

Westfield Capital Management Company, L.P.

9.03%

Avoro Capital Advisors LLC

8.25%

Janus Henderson Investors

7.33%

Fidelity Management & Research Company LLC

6.92%

其他

51.44%

持股股東

佔比

RA Capital Management, LP

17.03%

Westfield Capital Management Company, L.P.

9.03%

Avoro Capital Advisors LLC

8.25%

Janus Henderson Investors

7.33%

Fidelity Management & Research Company LLC

6.92%

其他

51.44%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

42.38%

Investment Advisor

37.12%

Venture Capital

17.36%

Hedge Fund

6.18%

Private Equity

1.87%

Research Firm

1.74%

Individual Investor

0.78%

Family Office

0.44%

Family Office

0.44%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

502

70.53M

116.83%

-1.34M

2025Q1

513

68.89M

114.10%

-3.55M

2024Q4

488

67.37M

111.00%

-7.76M

2024Q3

475

65.25M

107.66%

-6.23M

2024Q2

459

63.44M

108.94%

-9.21M

2024Q1

453

63.54M

109.13%

-8.68M

2023Q4

430

62.90M

109.00%

-9.55M

2023Q3

414

62.85M

109.61%

-11.90M

2023Q2

426

63.03M

109.93%

-13.27M

2023Q1

427

63.10M

110.08%

-9.14M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

RA Capital Management, LP

10.28M

17.03%

+168.75K

+1.67%

Mar 31, 2025

Westfield Capital Management Company, L.P.

5.48M

9.08%

-48.98K

-0.89%

Mar 31, 2025

Avoro Capital Advisors LLC

5.22M

8.64%

+114.94K

+2.25%

Mar 31, 2025

Janus Henderson Investors

4.49M

7.43%

+106.57K

+2.43%

Mar 31, 2025

Fidelity Management & Research Company LLC

4.30M

7.13%

-52.57K

-1.21%

Mar 31, 2025

Artisan Partners Limited Partnership

4.26M

7.05%

-193.79K

-4.35%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

3.05M

5.06%

+328.28K

+12.04%

Mar 31, 2025

Capital International Investors

2.87M

4.76%

+11.54K

+0.40%

Mar 31, 2025

MFS Investment Management

1.87M

3.1%

+9.63K

+0.52%

Mar 31, 2025

T. Rowe Price Associates, Inc.

2.26M

3.74%

-27.11K

-1.19%

Mar 31, 2025

持股ETF

更新時間: 8月6日週三

機構名稱

佔比

Harbor Health Care ETF

18.96%

American Century Focused Dynamic Growth ETF

2.5%

AdvisorShares Dorsey Wright ADR ETF

2.31%

BNY Mellon Innovators ETF

2.21%

Virtus LifeSci Biotech Products ETF

1.96%

Tema Heart & Health ETF

1.3%

ProShares Ultra Nasdaq Biotechnology

1.17%

Main Thematic Innovation ETF

1.05%

Invesco Nasdaq Biotechnology ETF

1.03%

Putnam Sustainable Future ETF

0.9%

Harbor Health Care ETF

佔比18.96%

American Century Focused Dynamic Growth ETF

佔比2.5%

AdvisorShares Dorsey Wright ADR ETF

佔比2.31%

BNY Mellon Innovators ETF

佔比2.21%

Virtus LifeSci Biotech Products ETF

佔比1.96%

Tema Heart & Health ETF

佔比1.3%

ProShares Ultra Nasdaq Biotechnology

佔比1.17%

Main Thematic Innovation ETF

佔比1.05%

Invesco Nasdaq Biotechnology ETF

佔比1.03%

Putnam Sustainable Future ETF

佔比0.9%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Ascendis Pharma A/S

194.620USD

Ascendis Pharma A/S

194.620

概覽

公司

財務

分析